Sanofi Collaborates with i2O Therapeutics to Evaluate Oral i2O Therapeutics

 Sanofi Collaborates with i2O Therapeutics to Evaluate Oral i2O Therapeutics

Sanofi Collaborates with i2O Therapeutics to Evaluate Oral i2O Therapeutics

Shots:

  • The companies collaborated to investigate oral delivery of Sanofi’s Nanobody based medicines, which are currently available in IV & SC formulations
  • The collaboration will advance the formulation of therapies that are traditionally limited to injections. Nanobodies are the therapeutic proteins based on camelid-derived immunoglobulin single variable domains & have potential to treat multiple diseases
  • Sanofi provides seed funding to i20 in Apr’2020 while the company received strategic investment from Colorcon Ventures in Dec’2020

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post